FAAH, fatty acid amide hydrolase, 2166

N. diseases: 177; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.070 GeneticVariation group BEFREE The aim of this study was to compare the effect of chronic administration of URB597, the FAAH (fatty acid amide hydrolase) inhibitor, to rats with primary (SHRs) and secondary (DOCA-salt hypertensive rats) hypertension on electrical and physicochemical properties of kidney cells membranes. 30502333 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.070 Biomarker group BEFREE Long-term administration of fatty acid amide hydrolase inhibitor (URB597) to rats with spontaneous hypertension disturbs liver redox balance and phospholipid metabolism. 30243113 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.070 Biomarker group BEFREE Here, we compared the effects of hypertension and chronic FAAH inhibition by URB597 on the endocannabinoid system and redox balance in spontaneously hypertensive rats (SHR) and hypertensive deoxycorticosterone acetate (DOCA)-salt rats. 30201316 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.070 Biomarker group BEFREE Chronic administration of fatty acid amide hydrolase (FAAH) inhibitor has potential protective properties on myocardial glucose metabolism in hypertension. 29621749 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.070 Biomarker group BEFREE Hypotensive effect of chronic FAAH inhibition depend on the model of hypertension and partly correlate with improved cardiac performance. 28437860 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.070 Biomarker group BEFREE This study revealed that chronic FAAH inhibition has no protective effects on the heart lipid metabolism in hypertension. 28633967 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.070 Biomarker group BEFREE The influence of DOCA-salt hypertension and chronic administration of the FAAH inhibitor URB597 on K<sub>Ca</sub>2.3/K<sub>Ca</sub>3.1-EDH-type relaxation in rat small mesenteric arteries. 29038048 2017